Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Slayback Pharma LLC, a Princeton, NJ based specialty pharmaceutical company, announced today the appointment of Pete A. Meyers as its Chief Financial ...
Slayback Pharma LLC (the "Company" or "Slayback"), a Princeton, NJ based specialty pharmaceutical company, announced today the appointment of Paul...
Slayback Pharma LLC (the "Company" or "Slayback") announced today the appointment of Dave Picard as the Company's Chief Commercial Officer. Dave will ...
Slayback Pharma LLC announces that it has launched Merzee (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1...
Slayback Pharma LLC announced today that it has received final approval for its Abbreviated New Drug Application (ANDA) for Merzee (norethindrone...
Slayback Pharma LLC ("Slayback") announced today the appointment of Dr Sumitra Pillai as Vice President and the new Head of R&D. Sumitra will be...
Slayback Pharma, LLC announced today that it has received final approval for its ANDA for Icatibant Injection 30 mg/3 ml (10 mg/ml) in a Prefilled...
Slayback Pharma LLC ("Slayback"), a privately-held, specialty pharmaceutical company, announced today the appointment of Lori A. Hoffman as Head of...
Slayback Pharma LLC ("Slayback") today announced an agreement with The Everstone Group ("Everstone") to invest up to US$50 million in Series B...
Slayback Pharma LLC announced today the final approval and launch in the United States of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride...
Slayback Pharma LLC announced today that it has received final approval for Hydroxyprogesterone Caproate Injection, USP 250 mg/ 1 ml. This is the...
Slayback Pharma LLC announced today that it has launched its first commercial product Hydroxyprogesterone Caproate Injection, USP 1,250 mg/ 5 ml....
Slayback Pharma LLC announced today that the U.S. Food and Drug Administration ("FDA") granted approval of its abbreviated new drug application...
Slayback Pharma LLC ("Slayback"), a privately held pharmaceutical research and development company, announced today the appointment of Dr Girish Jain ...
Slayback Pharma LLC ("Slayback"), a privately held pharmaceutical research and development company, announced today the appointment of Joan Janulis...
Slayback Pharma today announced that Founder & CEO, Ajay Singh, of Slayback Pharma LLC is the winner of the 32nd Ernst and Young's Entrepreneur Of...
Slayback Pharma today announced that CEO, Ajay Singh of Slayback Pharma LLC is named as one of the finalists for Ernst and Young's Entrepreneur Of...
Slayback Pharma LLC is pleased to announce the launch of Generic Zovirax Ointment (Acyclovir Ointment) 5%, by its out-licensee - Sandoz (Fougera)....
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.